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Abstract
Organoids have arisen as promising model systems in biomedical research 
and regenerative medicine due to their potential to reproduce the original tissue 
architecture and function. In the research field of cell–cell interactions, organoids 
mimic interactions taking place during organogenesis, including the processes 
that conduct to multi-lineage differentiation and morphogenetic processes, during 
immunology response and disease development and expansion. This chapter will 
address the basis of organoids origin, their importance on immune system cell–cell 
interactions and the benefits of using them in biomedicine, specifically their poten-
tial applications in regenerative medicine and personalized therapy. Organoids 
might represent a personalized tool for patients to receive earlier diagnoses, risk 
assessments, and more efficient treatments.
Keywords: organoids, cell-interactions, disease development, regenerative medicine, 
personalized therapy
1. Introduction
Most multicellular living organisms, especially vertebrates, develop from a 
single totipotent cell to a multicellular complex adult organism, reflecting an 
outstanding coordination and organization capacity. Furthermore, in some cases, 
after organ dissociation, cells can recombine and reconstruct the original structure. 
Researchers have used that feature to create organ-like structures from stem  
cells or tissues samples, leading to the formation of structures currently known as 
organoids [1].
Thus, organoids are self-organizing 3D structures derived from stem cells 
highly similar in structure and function to actual human organs. The different cell 
types and interactions guide and make possible this organization process. These 
structures resemble crucial aspects of the tissues from which derived and thereby 
organoids allow for biological relevant cell–cell and cell-matrix interactions. Those 
attributes make organoids technology a valuable tool in multiple applications such 
as developmental biology, molecular biology, and health studies like pharmacology, 
disease development and therapy, among others [2, 3].
The organoids field has exponentially accelerated in the last years, mainly after 
the application of appropriate culturing conditions that allow stem cells to dif-
ferentiate and participate in cell–cell interactions responsible of the community 
effect required for optimal resembling of self-organized tissue-like structures. 
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For instance, the use of Matrigel, a gel protein mixture that mimics the complex 
extracellular environment found in many tissues [4], has allowed the establishment 
of the right culture conditions required to achieve 3D cell cultures in vitro.
Organoids technology constitutes a step-forward approach for conventional 
cell-based research, full-filling the gap between 2D cultures and in vivo mouse/
human models. Organoids are physiologically more relevant than monolayer culture 
models, and allow easier manipulation of niche components, signaling pathways 
and genome editing than in vivo models [5].
Therefore, organoids represent a needed and also an advantageous approach 
in many senses. The organoids technology brings the opportunity to work with 
3D-tissue models at a “bench-side” level, opening a wide range of opportunities 
in basic and clinical research. Moreover, organoids also overcome the problems 
derived from using animal models to study human physiology and related-diseases. 
Although many results obtained in animal models can be easily extrapolated, some 
biological processes are specific to humans [6].
2. Organoids origin, structures and culture
Organoids can be derived from either [1] pluripotent stem cells (PSCs), includ-
ing embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) or [2] 
multipotent organ-specific adult stem cells (AdSCs). Both approaches take advan-
tage of the endless expansion potential of stem cells in culture. Also, when PSCs and 
AdSCs are allowed to differentiate in culture, they display a remarkable capacity 
to self-organize into structures that reflect similar characteristics of the organ they 
attempt to mimic [7].
PSCs can be differentiated into different cell types and grown ex vivo as organoid 
models by the treatment with defined developmental stimuli. PSCs isolated both 
from mouse and human tissues have given rise to brain, retina, inner ear, stomach, 
intestine, thyroid, lung, liver, and kidney organoids. ESCs or iPSCs can be derived 
in vitro into endoderm, mesoderm and ectoderm, with specific procedures involv-
ing multiple differentiation steps. Thus, human iPSCs are sequentially exposed to 
a progression of differentiation signals in order to simulate the stages of a human 
developmental process. Once the initial germ layer has arranged, cells are trans-
ferred into 3D systems [8], where differentiated iPSCs aggregate to form an organ 
bud and, later on, organoids. These organoids contain multiple cell types and faith-
fully mimic the mature organ structure, and the interactions between them.
As an example, embryoid bodies (EBs), 3D aggregates of PSCs, originate 
cerebral organoids and develop into a forebrain region in the presence of growth 
factors (i.e., hFGF basic, ROCK inhibitor, N2, Heparin, MEM-NEAA, etc.). For 
other organs, the addition of Activin A to PSCs specifies them towards an endoder-
mal fate. These cells are further cultured as 3D organoids in Matrigel with medium 
containing tissue-specific growth factors [9].
On the other hand, AdSCs-organoids can be originated from isolated adult 
stem/progenitor cells or from isolated tissue fragments of the corresponding organ 
(e.g. intestinal crypts, liver or pancreas ducts) [8]. These structures can be gener-
ated from biopsies isolated directly from the organ of interest or from diseased 
patient tissue without the complicated process of reprogramming and differentia-
tion required in iPSC organoids. In general, human AdSCs-derived organoids are 
composed mainly of cell types found in the epithelium.
AdSCs were long believed to be unable to proliferate outside the body, but the 
culture with specific growth factor cocktails mimicking stem cell niches, has helped 
to sort out such obstacle. These niche factors are essential to support stem cell 
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activity and vary depending on the tissue of origin. Also, 3D Matrigel-based cul-
tures have provided the appropriate culture conditions to generate AdSCs-derived 
organoids from various mouse and human tissues including the colon, stomach, 
liver, lung, prostate, pancreas, ovaries, taste buds, and lingual epithelium.
Thus, to generate AdSCs-organoids a tissue biopsy is cut into fine particles 
and then incubated with enzymes (i.e., collagenase, elastase, or dispase) to 
obtain a single cell suspension. Next, cells are grown in Matrigel and culture 
medium supplemented with specific tissue growth factors [9]. For example, 
intestinal organoids need Noggin, R-spondin, Epidermal growth factor (EGF), 
and WNT [10–12]; retina organoids need IWR1e and Smoothened agonist 
CHIR99021 [13, 14]; prostate organoids require Noggin, R-spondin and EGF 
[15], while pancreas organoids require Noggin, R-spondin, EGF, fibroblast 
growth factor (FGF) and Nicotinamine [16].
AdSCs organoids do not require genetic transduction with transcription factors, 
as it happens with those with PSCs. This situation makes organoids physiologically 
well-suited with the host tissue, leading to an improved stem cell transplantation. 
Moreover, molecular techniques such as clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-associated system (CRISPR-Cas9) genome 
technology and single-cell RNA sequencing, can be applied to organoids [7, 9]. On 
the other hand, the establishment of human AdSC-derived organoids is limited by 
the accessibility to the tissue and prior knowledge of the culture conditions for that 
tissue. However, an iPSC line, once established from a patient, can generate differ-
ent tissue models without any time limit, beyond the patient’s lifespan [17, 18].
3. Organoids in the immunology field
The knowledge concerning the interactions of the immune system with other 
tissues has been gained mainly from animal models and/or cell lines co-cultures. 
Nevertheless, some interactions between human cells cannot be addressed with 
murine models or cell lines which are usually transformed or genetically modified 
[19]. For instance, a specific immune cell morphology is required to maintain the 
tissue properties and, moreover, the immune system needs of multiple cell types 
interactions for appropriate functioning. Similarly, there are some aspects that can-
not be extrapolated in mice due to, for example, different protein pattern expres-
sions in human and mice. Thus, immunology researchers are starting to get the 
benefits of using organoids, for a better comprehension of the immune cell interac-
tions with other tissues, its development, homeostasis and in the bout of disease. 
The organoids approach maintains those cells in a near-native state, mimicking 
more accurately its original state and environment, providing researchers with a 
new effective tool.
The main challenge in the use of organoids in immunology resides in the fact 
that the organoids technology cultures only epithelial cells. However, a more com-
plete resource for immunological research can be developed by co-culturing these 
organoids with other elements.
The number of publications showing multiple co-cultures has spiked up in the 
past decade, particularly in the last five years [20–22]. In order to develop effective 
interventions to preserve health and defeat diseases it is necessary to know how 
immune cells coordinate their activities to initiate, modulate, and terminate inflam-
mation. Immune cells and molecules released by immune cells promote inflamma-
tion processes that are mediating the interactions between these cells [23].
These studies have revealed not only the importance of the presence (or 
absence) of immune cell derived factors in the epitheliums in culture, but also the 
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need of the reciprocal communication with the immune system. A work concerning 
the role of macrophages and fibroblasts on myoblast proliferation and migration 
highlights the importance of multicellular communication [24]. Thus, co-culture of 
either macrophages or fibroblasts with myoblasts prompted a significant increase in 
myoblast proliferation. Conversely, in the triple co-culture, although macrophages 
continued promoting myoblast proliferation, they had a negative effect over the 
ability of fibroblasts to enhance myoblast migration [25]. Another study, using 
single-cell transcriptomics, highlighted that intestinal stem cells can function as 
non-classical antigen-presenting cells for CD4+ T cells. Moreover, these interac-
tions, directly or through activated T cell-derived cytokines, seem to play a role in 
the intestinal epithelium differentiation [26].
The intestinal mucosal barrier function and the immune responses against 
invading pathogens seem to be regulated by the interaction between intestinal 
epithelial cells (IECs) and intraepithelial lymphocytes (IELs) [27]. IELs represent 
a heterogeneous population of activated and antigen-experienced T cells. A novel 
culture system of intestinal ‘enteroids’ has allowed the study of the complex 
interactions between IECs and immune peripheral T cells in long-term co-cultures. 
The development of these long-term co-cultures allowed the study of cell sur-
vival, proliferation, differentiation and IECs behavior. Moreover, IECs and T cells 
co-cultures revealed that peripheral T cells activated in the presence of enteroids 
acquire several features of IELs, including morphology, membrane markers and 
movement in the epithelial layer [27]. Similarly, mouse-derived enteroids co-
cultured with intestinal myofibroblasts and macrophages boosted their growth and 
differentiation [28].
In the same line, another study with intestinal organoids underlined the 
importance of the interactions between immune cells and other tissues for optimal 
maturation. In this work, the inclusion of the immune component (co-cultured 
with human T lymphocytes) into the differentiation protocol to form human 
pluripotent stem cell-derived intestinal organoids (hIOs) from hPSCs, enabled hIOs 
maturation. hIOs co-cultured with human T lymphocytes displayed expression lev-
els of mature intestinal markers equivalent to adult intestinal epithelium, as well as 
increased intestine-specific functional activities, retaining their maturation status 
even after their in vivo engraftment. This study has proven the needless for animal 
models and in vivo maturation when working with organoids [29].
Holokai, L. et al. were among the first researchers to successfully obtain a 
multiple organoid-co-culture involving cytotoxic T lymphocytes (CTLs) and 
Helicobacter pylori-infected gastric organoids. CTLs express programmed death 
1 (PD1) on the surface. When PD1 interacts with its ligand, CTLs cannot induce 
apoptosis. Thanks to this approach they discovered that PD-L1 signaling induces 
cellular proliferation and survival, leading to an increased expression of PD-1, IL-2 
and IFNγ in lymphocytes [30].
Overall, epithelial organoid cultures, whether derived from iPSCs or AdSCs, 
constitute a promising platform for immunological research for several applica-
tions, allowing, among others, to study immune cell–epithelial cell interactions 
in the context of pathogenic infections or sterile tissue damage [19]. In this sense, 
the vast majority of organoid studies about the immune system and its effects 
on epithelial differentiation and function have been performed on intestine-like 
structures. However, it would be useful to have similar works with different organ-
oid systems such as skin or lung, which also interact with both immune cells and 
commensal microorganisms [31].
Despite the amount of work already accomplished regarding the immune 
system, there is still a long way to go in inflammation research, due to the current 
lack of optimal immune cells organoids cultures.
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4. Organoids in the study and treatment of disease
Recent advances in the development of human patient-derived organoids have 
allowed a more accurate study of diseases. This technology has opened a new 
horizon in biomedical research, and provides unprecedented opportunities in 
translational medicine, and personalized therapy [32].
4.1 Disease modeling and drug screening approaches
Recent discoveries involving organoids as a disease model reflect that research-
ers have started to unravel the potential of this tool. To date, organoids have been 
mostly applied in cancer, cystic fibrosis and studies on host–microbe interactions. 
However, a growing interest in this field has promoted an exponential increase of 
publications using organoids technology to study many other diseases (Table 1). 
The fact that organoids are 3D structures originated from stem cells with similar 
architecture, multi-lineage differentiation and many of the original tissue func-
tions, make them the perfect candidate for disease pathogenesis studies [33, 34].
Organoids can be designed to reproduce patient conditions of disease-relevant 
genetic and epigenetics. Thanks to the development of new techniques like the 
CRISPR/CRISPR -Cas9 genome engineering tool, is currently feasible to efficiently 
manipulate genomic sequences in hESCs and hiPSCs [35, 36]. In the case of host–
microbe interactions, organoids can also reproduce the infection process allowing 
its study in more life-like manner.
Organoids can also be applied to study cellular dysfunction in diseased tissues, 
as well as to identify strategies for its restoration. For example, Dekkers et al. used 
organoids to study cystic fibrosis (CF), a disease caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene, severely reducing the CFTR 
protein function [37]. Thus, rectal organoids from CF patients were used to evalu-
ate CFTR function as well as the response to CFTR-modulating drugs. Their results 
demonstrated the pharmacological restoration of CFTR function in the rectal 
organoids of individual donors, suggesting that in vitro functional measurements 
of CFTR may be used to preclinically identify CF patients who would benefit from 
CFTR-modulating treatments, independent of their CFTR mutation [38].
A major challenge in clinical practice is the absence of appropriate models for 
drug screening and pre-evaluation of the pharmacological effects prior administra-
tion to patients. For cancer research, the development of tumor organoids, also 
known as tumoroids, represents an overwhelming step to be able to reproduce in 
vitro such a heterogeneous microenvironment. Tumor organoids can be generated 
in vitro for the analysis of cancer phenotypes [39], anticancer drug discovery, and to 
evaluate the response of patient cancer cells to a specific treatment [39, 40]. Lazzari 
et al. reported a triple co-culture of pancreatic cancer cells fibroblasts and endothe-
lial cells. As a result, cells assembled in a hetero-type multicellular tumor-spheroid 
(MCTS) that reliably reproduced the impact of the surrounding environment, on 
the sensitivity of cancer cells to chemotherapy. This approach can be successfully 
applied as a predictive tool of various therapeutic strategies [41]. In this sense, 
the establishment of patient-derived tumor organoids (PDTO) biobanks provides 
exciting new insights into developmental biology. Different researchers have started 
to develop methods for generating and bio-banking PDTO. Among them, a non-
profit organization called HUB (Hubrecht Organoid Technology) has initiated 
and established “Living Biobank”, a collection of organoids representing different 
organs and disease models (huborganoids.nl). Overall, these biobanks maintain the 
key features to resemble the parental tumors and can be therefore used to evaluate 
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Salivary gland a a a Hyposalivation [46]
Thyroid a a a Cancer [47]
Lung a a a a a Cystic fibrosis [24]
Cancer [48]
Breast a a a a a Cancer [49]
Esophagus a a a Barrett’s esophagus [50]
Cancer



























Tissue of origin AdSC-derived PSC-derived Cancer biobank Disease References
Human Mouse Human Mouse
Intestine a a a a a Infectious diseases [10–12]
Cystic fibrosis [26, 28, 29]
Cancer [52, 53]








Liver a a a a a Alagille syndrome [56–58]




Kidney a a a a a Polycystic kidney disease [59, 60]
Cancer
Female reproductive tract a a a a a Cancer [36, 61]
Prostate a a a a a Cancer [15, 62]
Table 1. 
Use of organoids as disease models.
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Jacob et al. reported the generation of patient-derived glioblastoma organoids 
(GBOs) biobanks [42]. The authors successfully transplanted the GBOs into adult 
rodent brains and performed personalized tests. Calandrini et al. have recently 
established the first pediatric cancer organoid biobank [59]. This biobank contains 
a collection of over 50 tumors matching normal kidney organoids and also cov-
ers a diversity of tumor subtypes. Similarly, a primary gastric cancer organoid 
(GCO) biobank was established by Leung and coworkers [63], including a total 
of 34 patients with different gastric cancer subtypes. In this study, whole-exome 
sequencing and transcriptome analysis were performed, as well as large-scale drug 
screening studies. Overall, the establishment of organoids biobanks provides a rich 
resource for cancer cell biology and drug-screening studies to test personalized 
therapies. Patient-specific drug sensitivities could be achieved as the organoids 
closely resemble the in vivo tumors. Furthermore, these biobanks could play a 
prominent role in biomarker discovery and represent a powerful tool to predict 
disease development, recurrence and progression [42, 51, 64].
4.2 Applications in regenerative medicine
Several of the most life-threatening diseases require organ transplantation in 
order to save patients life. Nevertheless, transplantations are not always an option 
due to the high cost, organ availability or potential organ rejection. Therefore, 
other alternatives needed to be explored in order to overcome this challenge. The 
development of organoids brought hope to the scientific community and patients 
themselves. This technology could potentially serve as an unlimited source for 
replacing damaged tissues. Furthermore, the transplantation of organoids derived 
from healthy tissue of the same patient would prevent immune responses related 
to non-autologous transplants. In this sense, diseases involving dysfunctional 
organs such as kidneys or the liver, can significantly benefit from the opportunity 
that liver-derived organoids bring. Researchers have already developed strategies 
to allow long-term in-vitro expansion of liver progenitors into “liver organoids” 
[56]. The huge expansion and differentiation potential of liver organoids cultures 
has facilitated the engraftment [56] and survival of livers in murine models, as it 
happened in a study with liver organoids transplanted to a tyrosinemia type I liver 
disease model, partially restoring the hepatic function [57]. Similarly, transplanta-
tion of human adult stem cell-derived liver organoids into chemically damaged-liver 
immune-deficient mice produced functional hepatocytes containing grafts [58]. 
Cultured organoids have also shown the potential to expand, engraft, reconstitute 
and recover the colon and intestinal epithelia as well as their function in several 
murine models [52–54].
Despite all the advances in the field, there is still a long way before organoids 
transplantation becomes a reality. Current resources and techniques do not provide 
a suitable organ niche, limiting the formation of optimal organ sizes and tissue 
structures in vivo, as well as the appropriate intercellular communication required 
for functional restoration. Thus, alternative approaches are required, such as the 
combination of organoids with gene therapy, to implement organ transplantation 
[65]. Experts on the field will still have to poise excitement with reality before 
organoid research can be successfully translated to clinical practice and become a 
real therapy option [66].
4.3 Personalized medicine
Over the past decades, medicine has discovered novel ways of changing the 
course of many human diseases [67–70]. Nowadays, researches all over the globe 
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are discovering new therapies which bring new options for previously untreatable 
diseases [71, 72]. However, the key challenge is that the efficacy of most of these 
new treatments will depend on the complex and unique nature of each individual 
human being. Lastly, the efficacy of a treatment is significantly determined by 
behavioral factor, environmental influences as well as genetic particularities.
Moreover, currently available therapies might cause a high impact on patient’s 
quality of life due to the unpleasant side effects directly related to the treatment. 
Thus, research groups and pharmaceutical companies are developing strategies 
to personalize their treatments in order to predict the outcome of the proposed 
therapy and avoid unnecessary aggressive treatments. These aspects are key to 
achieve the ultimate goal of any therapy: to ensure patients´ health and integrity.
The concept of Personalized Medicine arose with the aim of tailoring the best 
response and highest safety standards to preserve patient’s well-being. This opti-
mized health care strategy would also lead to reduced treatment costs and shorter 
diagnosis times required for each patient [73–75].
Organoids have revolutionized personalized medicine due to their unique ability 
of simulate, even mimic, specific cellular microenvironments with remarkable simi-
larity to in vivo organs/tissues under normal or pathological conditions [76]. Such 
models have started to be used in the clinic, mainly in cancer research, to evaluate 
the response to experimental therapies prior administration of certain drugs or 
other treatments to patients [77]. The possibility of using accessible models of 
organ diseases allows to understand the effect of experimental therapy in a deeper 
manner than in a traditional culture assay or “sphere” culture assays, applied over 
the last decades [78].
Personalized medicine could also be linked to regenerative medicine which is 
based on the capacity of the stem cells to derive into many different cell subtypes. 
Currently, this basic characteristic is key for the understanding of normal and 
abnormal cell behavior and organization, and is leading to improved tissue engi-
neering approaches [60].
In this scenario, organoids constitute a solid foundation on which personalized 
and regenerative medicine is taking long steps forward.
One of the best examples of this input on current society is the novel application 
of organoids cultures to optimize treatment to cancer patients [55, 79]. Oncologic 
centers are developing translational procedures to understand as much as possible 
the specific characteristics of each tumor in order to optimize the therapy approach.
Once the tumor is detected, a biopsy of the mass is obtained to culture organ-
oids derived from patient’s tumor cells. A complete biological profile of the tumor 
could be developed combining this information together with histopathological 
analysis of primary tumor sample, histopathological analysis of the organoids, 
gene sequencing and cytotoxicity analysis from in vitro drug assays or studies using 
avatar mice.
This complete analysis only takes 2–4 weeks and it could provide physicians 
relevant information regarding the best treatment for the patient according to the 
characteristics of the tumor.
Furthermore, in cases of progressive disease or metastasis, new tumor biopsies 
could be collected, new organoids lines could be established, and new therapeutic 
strategies could be carried out giving a new opportunity and new hopes to the 
patient [80–82].
According to the website ClinicalTrials-gov, by 2019 there were 30 projects 
related to cancer organoids. Most of them (73%) focused on studying anti-cancer 
therapies, including among others T-cell immunotherapy, or evaluation of radio-
therapy sensitivity. The rest aimed to generate patient-derived cancer organoid 
models (13%) or to evaluate the mechanisms related to cancer progression [83].
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A large number of cancer patients are insensitive to immunotherapy due to the 
heterogeneity of the T cell repertoire [83]. Thus, the use of cancer organoids allows 
studying the effectiveness of combining immune therapy with specific anti-cancer 
drugs. To date, two clinical trials involving cancer organoids for immunotherapy 
have been registered (NCT03778814, NCT02718235). Overall, the inclusion of 
PDTO into clinic represents an enormous potential to understand the onset of dis-
eases such as cancer and, moreover, to evaluate the individual response to specific 
therapies for personalized approaches.
5. Limitations and future perspectives
Regardless of the advances made in this emerging technology, a series of limita-
tions still need to be addressed in order to fully exploit its potential. For instance, 
despite the development of specific culture conditions and growing techniques, 
there are still tissues that withstand to organoid derivation [84, 85]. Organoid 
technology requires further advances to achieve less laborious protocols as well as 
the establishment of standardized conditions for proper differentiation and matu-
ration. A reduction of the heterogeneity seen in organoids size and shape should 
also be achieved [85]. In addition, it requires the co-induction of the essential cell 
types, the associated extracellular matrices and native microenvironment that 
will allow the recapitulation of the in vivo tissue sizes, structures, organization, 
inter-cellular communication and functionality. Also, shorter processes and more 
affordable culture conditions are required to ensure that the organoids system 
becomes accessible to a large number of academic and clinical researchers, thereby 
helping to maximize its potential [5]. Moreover, the protocols used for generating 
one specific type of organoid are usually not transferable to another organ system. 
Due to this drawback, scalable and cross-system parameters are challenging to gen-
erate via bioengineering tools. Computational prediction models are also difficult to 
design limiting the capacity to predict phenotypic, toxicological and drug screen-
ing results. Lastly, organoids technology requests the development of a complex 
vasculature network to provide not only oxygen, nutrient and waste exchange, but 
also an inductive biochemical exchange and a structural template for growth. The 
advances in microvascular patterning and organ-on-a-chip microfluidic technology 
would bridge this limitation supporting the use of perfusable organoids generation 
[86, 87].
In this context, different strategies are currently under research and new ideas 
have arisen to implement the potential use of organoids. As stated before, the 
development of organoid biobanks constitutes an important step in this direction. 
Currently, there are organoid biobanks with healthy organoids as well as patient-
derived intestine, liver, pancreatic, lung and mammary gland organoids related to 
cancer, cystic fibrosis or inflammatory bowel disease [88]. Thus, organoid biobanks 
are becoming a demanding business and several companies worldwide have already 
started to commercialize organoids after the establishment of optimized organoid 
biobanks [88]. Advantages of organoid biobanks include immediate accessibility 
or cost-effectiveness, as well as the possibility to access a large repository of data 
related to patient’s diseases [83, 88]. This, however, involves some ethical and regu-
latory challenges that need to be addressed such as donor confidential information 
or the organoid source itself [89].
The development of microfluidic organoid-on-a-chip platforms [90] and 
3D bioprinting [91, 92] constitute two major advances in the last years that are 
contributing to speed up organoid manufacturing and commercialization [88]. 
Organ-on-a-chips are devices containing living cells, extra-cellular matrix (ECM) 
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and microstructures emulating key features of organs or issues, and their functions 
[83, 93]. These devices aim to provide continuous flow perfusion culture to simulate 
organ microenvironments. Nevertheless, most of these systems are made of pri-
mary cell lines or stem-cell-derived cells to mimic organs, but they are unable yet to 
imitate the cellular interactions taking place in the native sources [94].
Similarly, advances in 3D printing technology and biomaterials research have led 
to the creation of 3D bioprinting, with the aim to resemble in vitro the interactions 
between tumor cells, ECM and the 3D tumor microenvironment [83, 95]. With this 
technology, different cell types can be printed in hydrogels and mixed with other 
cells and/or specific factors to simulate a healthy or pathological microenvironment. 
Increasing evidence has pointed to the tumor microenvironment as a major modula-
tor of the tumorgenic process [96]. Thus, in order to understand the mechanisms by 
which tumor cells become metastatic, different studies are benefiting with the use 
of 3D bioprinting strategy. For example, Grolman JM et al. designed a 3D environ-
ment with breast adenocarcinoma and macrophage cell lines printed in hydrogel to 
evaluate the effect of paracrine signals in the regulation of breast cancer metastasis 
[97]. In the same way, Pang Y et al. developed an in vitro cervical tumor model to 
demonstrate the epithelial-to mesenchymal transition (EMT), by mixing HeLa cells 
with hydrogel. These authors were able to evaluate the effect of different activators 
and inhibitors over the EMT in the 3D system designed [98].
Despite the benefits of using these techniques, there are still several factors that 
need to be optimized. For instance, biomaterials represent a limiting feature for 3D 
bioprinting, and the development of improved materials is required. A consensus in 
the best printing strategy (i.e. polymerization steps, light-based 3D bioprinting vs 
inkjet printing) should be also reached.
6. Conclusions
This chapter focused on the advantages of using organoids to expand our 
knowledge in the field of cellular interactions. We have focused specifically in 
immunology and disease-related research, going through some of the latest or more 
relevant publications involving organoids. Overall, organoids constitute an efficient 
tool to study immune cells´ interactions in vitro in 3D-tissue models that provide a 
closer view of the interactions taking place in vivo. Moreover, organoids represent a 
promising approach in the development of autologous tissue-based cellular thera-
pies, especially in life-threatening diseases. Nevertheless, despite the organoids 
relevance, the growing interest in these structures and their potential applications, 
there is still a long way to go to achieve the translation of organoids into clinical 
practice. The development of bioengineering tools such as microfluidic organ-on-
a-chip platforms or 3D bioprinting systems represents a huge step in this direction. 
These strategies could provide consistent nutrients and factors required to emulate 
3D tissue physiology in vivo. The optimal conditions are not yet established and 
further research is required before results can be undoubtedly extrapolated and 
clinical applications implemented. Nevertheless, the growing interest in organoids 
commercialization will probably help to speed up the translation of organoids to the 
clinic.
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